ONLINE APPLICATION

+373 (22) 81 90 90

+373 68 287 728

Sign up for the sample or get a consultation

Why ONCOGENE?

WE ARE INNOVATIVE

The emergence of genomic technologies, such as next-generation sequencing (NGS), enables the industry and academic environment to offer products and services, which allows doctors to interpret patient data using technologies for complex intelligent analysis of clinical information in real time.


WE ALWAYS USE ONLY THE LATEST DATA

ONCOGENE offers personalized, structured medical reports of cancer patients, containing information of the detected genetic mutations of the tumour, complex contexts of interaction between individual mutations, mechanisms of disease, all types of genomic changes, potentially effective and potentially ineffective anticancer drugs, data on their toxicity, adverse events and drug interactions etc.

WE GUARANTEE THE ACCURACY AND QUALITY

Medical reports are generated using a diagnostic device (software) MH Guide® (CE-IVD), registered in Europe, which is intended for clinical interpretation of genomic data of patient's tumour, and obtained as a result of whole-exome sequencing of DNA tumour. Information contained in the report, and intended for medical oncologist, is the result of complex comparative analysis of genomic profile of the tumour of specific patient with relevant global biomedical and pharmacological data and knowledge.

WE GUARANTEE THE SECURITY OF PATIENT DATA

ONCOGENE guarantees the use of genetic information only in the interest of the patient. This is achieved by implementing and using of standards for the transmission of genetic information. ONCOGENE guarantees the patient's right to be informed and make decisions about the results of genetic testing, as well as complete confidentiality.

 
SERVICE

PERSONALIZED APPROACH TO CANCER TREATMENT


Read more
2018 - 2020
Adverse Event Circumstances and the Case of Drug Interactions

Soldatos, Jackson.

Healthcare (Basel). 2019 Mar 19;7(1). pii: E45. doi: 10.3390/healthcare7010045.


Adverse events are a common and for the most part unavoidable consequence of therapeutic intervention. Nevertheless, available tomes of such data now provide us with an invaluable opportunity to study the relationship between human phenotype and drug-induced protein perturbations within a patient system...


Află mail mult
Precision Oncology - The Quest for Evidence

Soldatos TG, Kaduthanam S, Jackson DB.

2019 Sep 5;9(3). pii: E43. doi: 10.3390/jpm9030043.


The molecular characterization of patient tumors provides a rational and highly promising approach for guiding oncologists in treatment decision-making. Notwithstanding, genomic medicine still remains in its infancy, with innovators and early adopters continuing to carry a significant portion of the clinical and financial risk...


Află mail mult
Target‐Adverse Event Profiles to Augment Pharmacovigilance: A Pilot Study With Six New Molecular Entities

Peter Schotland, Rebecca Racz, David Jackson, Robert Levin, David G. Strauss and Keith Burkhart

24 October 2018


Clinical trials can fail to detect rare adverse events (AEs). We assessed the ability of pharmacological target adverse‐event (TAE) profiles to predict AEs on US Food and Drug Administration (FDA) drug labels at least 4 years after approval...


Află mail mult
Association Between Serotonin Syndrome and Second-Generation Antipsychotics via Pharmacological Target-Adverse Event Analysis

Racz, Soldatos, Jackson, Burkhart.

Clin Transl Sci (2018) 00, 1–8; doi:10.1111/cts.12543


Case reports suggest an association between second-generation antipsychotics (SGAs) and serotonin syndrome (SS). The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) was analyzed to generate hypotheses about how SGAs may interact with pharmacological targets associated with SS...


Află mail mult
In Silico Profiling of Clinical Phenotypes for Human Targets Using Adverse Event Data

Soldatos, Taglang, Jackson

High Throughput. 2018 Nov 23;7(4). pii: E37. doi: 10.3390/ht7040037


We present a novel approach for the molecular transformation and analysis of patient clinical phenotypes. Building on the fact that drugs perturb the function of targets/genes, we integrated data from 8.2 million clinical reports detailing drug-induced side effects with the molecular world of drug-target information...


Află mail mult
Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data

Soldatos

Diagnostics (Basel). 2018 Oct 31;8(4). pii: E76. doi: 10.3390/diagnostics8040076


Recent studies suggest that combining nivolumab with ipilimumab is a more effective treatment for melanoma patients, compared to using ipilimumab or nivolumab alone. However, treatment with these immunotherapeutic agents is frequently associated with increased risk of toxicity, and (auto-) immune-related adverse events...


Află mail mult
Find out more about our latest news